Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Thermo Fisher Scientific Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals, Inc.

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.

Avalon GloboCare Corp.

Cepheid provides molecular diagnostic testing for various health conditions, including infectious diseases and oncology. It offers diagnostic systems and services to healthcare professionals.

Metric
Company Name	Thermo Fisher Scientific Inc.	Alnylam Pharmaceuticals, Inc.	Avalon GloboCare Corp.	Cepheid
Symbol	TMO	ALNY	AVCO
MSH ID	COM:THERMOFISHER	COM:ALNYLAM	COM:AVALON-GLOBOCARE	COM:CEPHEID
Market	STOCKS	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Healthcare	Real Estate	Healthcare & Health Services
Industry	Medical - Diagnostics & Research	Biotechnology	Real Estate - Services	Healthcare Technology
Country	US	US	US	US
Stage			Post-IPO
Employee Count	122K	2.10K	5	4.86K
Website	thermofisher.com	alnylam.com	avalon-globocare.com	cepheid.com
LinkedIn
Founders

Metric
Market Cap	204.93B	32.60B	5.26M
Enterprise Value
Monthly Web Traffic		55.97K	88	95.72K
Web Traffic Growth		0.89	-0.85	0.47
Valuation
Raised Capital		900M	20M	63.80M

Metric
Revenue	42.86B	1.83B
Revenue (LTM)
Revenue (NTM)
Gross Profit	17.56B	1.52B
EBITDA	6.86B	-228.12M
Operating Income	6.86B	-282.18M
Net Income	6.00B	-440.24M
EPS	15.53	-3.52
Diluted EPS	15.45	-3.52
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.42	0.87
Operating Profit Margin	0.17	0.04
EBITDA Margin	0.16	-0.12
Net Profit Margin	0.15	-0.03
Return on Equity	0.13	1.67
Return on Assets	0.06	-0.02
Return on Capital Employed	0.09	0.03

COM:THERMOFISHER

Thermo Fisher Scientific Inc.

Last Close

516.10

22/11 21:00

Market Cap

204.93B

Beta: -

Volume Today

1.61M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	35.85	-42.10
P/B Ratio	4.70	-129.43
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.61	16.84
EV Multiple	20.87	326.32

Metric
Days Sales Outstanding	70.36	68.92
Days Payables Outstanding	35.73	97.72
Days Inventory Outstanding	76.60	128.53
Operating Cycle	157.60	187.09
Cash Conversion Cycle	145.06	104.98
Asset Turnover	0.44	0.58

Metric
Operating Cash Flow	8.41B	104.16M
Free Cash Flow	6.93B	41.95M
Cash Flow to Debt	0.26	0.15
Operating Cash Flow/Sales	0.22	0.16
Free Cash Flow Yield	0.03	-0.00

Metric
Cash & Equivalents	8.08B	812.69M
Accounts Receivable	-43M	-87.94M
Inventory	5.09B	89.15M
Goodwill	44.02B
Debt to Capitalization	0.44	1.20
Debt to Assets	0.36	0.34
Current Ratio	1.63	3.14
Quick Ratio	1.37	3.07

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	-0.00	0.13
R&D to Revenue	0.03	0.58
SG&A to Revenue		0.35